Halozyme Therapeutics, Inc. Earnings

Halozyme Therapeutics, Inc.’s revenue jumped 34.28% since last year same period to $290.08Mn in the Q3 2024. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 25.39% jump in its revenue since last 3-months.

Halozyme Therapeutics, Inc.’s net profit jumped 67.42% since last year same period to $137.01Mn in the Q3 2024. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 46.94% jump in its net profits since last 3-months.

Halozyme Therapeutics, Inc.’s net profit margin jumped 24.68% since last year same period to 47.23% in the Q3 2024. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 17.19% jump in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc.’s price-to-earnings ratio after this Q3 2024 earnings stands at 15.67.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.98 - a 28.95% jump from last quarter’s estimates.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.98.

Halozyme Therapeutics, Inc.’s earning per share (EPS) jumped 69.33% since last year same period to 1.27 in the Q3 2024. This indicates that the Halozyme Therapeutics, Inc. has generated 69.33% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Halozyme Therapeutics, Inc.’s return on assets (ROA) stands at 0.15.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Halozyme Therapeutics, Inc.’s return on equity (ROE) stands at 1.12.